AbbVie Inc

AbbVie develops, manufactures, and sells prescription medicines across several core areas: immunology drugs for autoimmune diseases, oncology treatments for various cancers, neuroscience medications for conditions like migraine and Parkinson's disease, and aesthetic products including Botox and facial fillers [Company Overview]. The company also offers eye care products and treatments for hepatitis C and gastrointestinal conditions [Company Overview].

AbbVie is a major pharmaceutical company with $61.2 billion in annual revenue [Yahoo Finance], focused on treatments for autoimmune diseases (Skyrizi, Rinvoq), blood cancers (Imbruvica, Venclexta), and neurological conditions (Vraylar, Botox) [Company Overview]. The company generates strong cash flow ($17.8 billion free cash flow) and maintains a 70% gross margin [Yahoo Finance], though it carries significant debt (3.4x net debt to EBITDA) and trades at an extremely high valuation (105x earnings) [Yahoo Finance].

AbbVie is financially healthy with strong cash generation, though burdened by substantial debt and an elevated valuation.